Renaissance Technologies’s Phathom Pharmaceuticals PHAT Stock Holding History

Renaissance Technologies’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.46M	Sell	226,400 -79,400	-26%	-$906K	﹤0.01%	1850
2026 Q1	$3.4M	Buy	+305,800	New	+$3.86M	0.01%	1591
2024 Q1	–	Sell	-65,600	Closed	-$599K	–	3984
2023 Q4	$599K	Buy	+65,600	New	+$565K	﹤0.01%	2704
2023 Q3	–	Sell	-10,000	Closed	-$143K	–	3991
2023 Q2	$143K	Buy	+10,000	New	+$115K	﹤0.01%	3381
2022 Q3	–	Sell	-24,000	Closed	-$203K	–	4328
2022 Q2	$203K	Buy	+24,000	New	+$247K	﹤0.01%	3645
2021 Q2	–	Sell	-11,300	Closed	-$424K	–	3700
2021 Q1	$424K	Buy	+11,300	New	+$473K	﹤0.01%	2974

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Renaissance Technologies's PHAT Position: Q2 2026 in Review

Renaissance Technologies reduced its Phathom Pharmaceuticals (PHAT) stake by 26% in Q2 2026, selling an estimated $906K and leaving 226,400 shares worth $2.46M. The position accounts for ﹤0.01% of the portfolio, ranked #1850.

Renaissance Technologies first reported a position in PHAT in Q1 2021 and has held it in 6 quarters since. The position peaked at $3.4M in Q1 2026. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

Renaissance Technologies held 226,400 shares of Phathom Pharmaceuticals worth $2.46M as of Q2 2026.
Renaissance Technologies sold 79,400 Phathom Pharmaceuticals shares in Q2 2026, an estimated $906K.
Phathom Pharmaceuticals made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #1850 holding.
Renaissance Technologies first reported a position in Phathom Pharmaceuticals in Q1 2021 and has held it in 6 quarters since.
Renaissance Technologies's Phathom Pharmaceuticals position peaked at $3.4M in Q1 2026.
162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.